Skip to main content

Table 1 Summary information of studies included in the meta-analyses.

From: ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation

First author, Year, Country [ref]

Study design, duration of FU

Cohort description [No of patients (M/F), Ethnicity, Mean Age (SD), inclusion criteria]

Restenosis definition criteria

Intervention

Gene-gene interaction assessed? (gene)

Quality score

    

Balloon angioplasty

  

Volzke, 2000, Germany [17]

cohort

6 months

511 (388/123), Caucasians, 60.6 (8.6), CAD patients undergoing elective PTCA of a previously untreated native coronary artery

> 50% progression of the residual stenosis at FU

PTCA-balloon

No

35

Yoshida, 1999, Japan [18]

cohort

5.21 (3.9) years

123 (nr), East Asians, 58.2 (10.2), MI patients undergoing PTCA discharged from hospital at the start of FU

nr

PTCA-balloon

No

30

Kasi, 1996, Spain [19]

cohort

6 months

69 (57/12), Caucasians, 58 (9.9), UA patients undergoing PTCA

diameter stenosis > 50% at FU

PTCA-balloon

No

27

Kamitani, 1995, Japan [20]

cohort

6 months

103 (103/00), East Asians, 52 (1), Primary PTCA for MI patients

> 50% progression of the residual stenosis at FU

PTCA-balloon

No

27

Samani, 1995, UK [21]

cohort

4 months

233 (194/39), nr, 56 (1), single-vessel PTCA in the Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) study

> 50% progression of the residual stenosis at FU

PTCA-balloon

No

34

van Bockxmeer, 1995, Australia [22]

cohort

6 months

207 (170/37), Caucasians, 57 (9), CAD patients undergoing elective PTCA

> 50% progression of the residual stenosis at FU

PTCA-balloon

Yes (APOE)

33

Tsukada, 1997, Japan [23]

cohort

3 months

96 (nr), East Asians, 60 (1.0), CAD patients undergoing elective PTCA

diameter stenosis > 50% at FU

PTCA-balloon

No

28

Beohar, 1995, USA [24]

cohort

3 months

89 (nr), Caucasians, 63.9 (10), CAD patients undergoing elective PTCA

diameter stenosis > 50% at FU

PTCA-balloon

No

24

Zee, 2001, Spain [25]

cohort

6 months

342 (305/37), Caucasians, 58.9 (9.6), CAD patients undergoing PTCA

> 50% progression of the residual stenosis at FU

PTCA-balloon

No

37

Ohishi, 1993, Japan [26]

cohort

6 months

82 (nr), East Asians, nr, MI patients undergoing primary PTCA

> 50% progression of the residual stenosis at FU

PTCA-balloon

No

23

Hamon, 1998, France [37]

cohort

6 months

271 (229/42), Caucasians, 60 (10), CAD patients undergoing PTCA

diameter stenosis > 50% at FU

PTCA-balloon

Yes (AGT1R)

34

    

Angioplasty with stent deployment

  

Amant, 1997, France [30]

cohort

6 months

146 (117/29), Caucasians, 60 (10) CAD patients undergoing PTCA

diameter stenosis > 50% at FU

PTCA-STENT

No

37

Wijpkema, 2006, Netherlands [29]

cohort

9 months

2888 (2050/838), Caucasians, 62 (11), CAD patients undergoing elective PTCA

death from cardiac causes, MI attributable to target vessel and target vessel revascularization

PTCA-STENT

Yes (AGT, AGT1R, AGT2R, HMOX1)

35

Gomma, 2002, UK [31]

cohort

6 months

205 (155/50), Caucasians, 59.4 (9.9), CAD patients undergoing PTCA

diameter stenosis > 50% at FU

PTCA-STENT

No

27

Ruy, 2002, Korea [32]

cohort

6 months

238 (178/60), East Asians, 59.5 (9.9), CAD patients undergoing PTCA

diameter stenosis > 50% at FU

PTCA-STENT

Yes (CYP11B2, AGT)

32

Ribichini, 2004, Italy [33]

cohort

6 months

897 (160/737), Caucasians, 61 (10), CAD patients undergoing PTCA

diameter stenosis > 50% at FU

PTCA-STENT

No

33

Taniguchi, 2001, Japan [34]

cohort

6 months

67 (50/17), East Asians, 65.2 (9.7), CAD patients undergoing PTCA

> 50% progression of the residual stenosis at FU

PTCA-STENT

No

23

Koch, 2000, Germany [35]

cohort

1 year

1850 (1458/392), Caucasians, 62.9 (10), CAD patients undergoing PTCA

diameter stenosis > 50% at FU

PTCA-STENT

No

40

Gurlek, 2000, Turkey [36]

cohort

6 months

132 (112/20), Turks, 53 (9), CAD patients undergoing PTCA

diameter stenosis > 50% at FU

PTCA-STENT

No

29

Guneri, 2005, Turkey [43]

cohort

9 months (2.9)

94 (59/35), Turks, 59.6 (9.9), CAD diabetic patients undergoing PTCA for stable angina pectoris

diameter stenosis > 50% at FU

PTCA-STENT

No

26

    

Angioplasty with ACEi treatment

  

Ribichini, 2003, Italy [42]

Cohort

6.3 (2.5) months

271 (nr), Caucasians, 61 (10), CAD patients undergoing PTCA

diameter stenosis > 50% at FU

PTCA-STENT + ACEi

No

35

Okamura, 1999, Japan [44]

cohort

6 months

97 (84/13), East Asians, 60 (2), CAD patients undergoing PTCA for stable angina pectoris

diameter stenosis > 50% at FU

PTCA-balloon + Imidapril 5 mg

No

29

Okumura, 2002, Japan [45]

cohort

6 months

92 (73/19), East Asians, 64.3 (8.9), CAD patients undergoing PTCA

diameter stenosis > 50% at FU

PTCA-STENT + Quinapril 18 mg

No

22

Ferrari, 2002, multicenter (Europe) [46]

cohort

6 months

154 (119/35), Caucasians, 61 (9.9), CAD patients undergoing PTCA

> 50% progression of the residual stenosis at FU

PTCA-STENT + ACEi

No

36

Jorgensen, 2001, Netherlands [49]

cohort

6 months

369 (293/76), Caucasians, 59 (43–73), CAD patients undergoing PTCA for stable angina

diameter stenosis > 50% at FU

PTCA-STENT + ACEi

No

40

  1. Abbreviations: DCA: directional coronary atherectomy, FU: follow-up, UA: unstable angina, MI: myocardial infarction, RCT: randomized controlled trial, ACEi: angiotensin converting enzyme inhibitors, nr: non-reported